Eversheds says Sun Pharmaceuticals deal represents opportunity in generics market
Eversheds partner Richard Lewis has commented on Sun Pharmaceuticals’ acquisition of Ranbaxy.
Lewis said: ‘This deal is a clear sign of further consolidation in the Indian generics market as companies look to increase market share, enhance growth opportunities and reduce costs.
‘As the country’s largest pharma company, it will now be particularly well placed to capitalise on the fast-growing Indian pharmaceuticals market.’
News from Eversheds
News from The Lawyer
Briefings from Eversheds
The most important advantage of international arbitration is the enforceability of its result, as a deal is only as reliable as the mechanism by which it can be made legally enforceable.
The Court of Appeal decision in CLP Holding Company Ltd v Singh (1) Kaur (2) prompts consideration of a common oversight in dealing with dilapidations claims.
Analysis from The Lawyer
A new breed of lawyer is smoothing the path for companies entering emerging or unstable jurisdictions
‘Exotic’ investors and opportunities for legal work beyond M&A feature in The Lawyer’s high-level roundtable debate on south-east Europe